Our top pick for
BGC Partners Inc is a capital markets business based in the US. BGC Partners shares (BGCP) are listed on the NASDAQ and all prices are listed in US Dollars. BGC Partners employs 4,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.52|
|52-week range||$2.42 - $6.50|
|50-day moving average||$5.26|
|200-day moving average||$5.51|
|Wall St. target price||$7.00|
|Dividend yield||$0.04 (0.73%)|
|Earnings per share (TTM)||$0.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||0.55%|
|1 month (2021-09-27)||5.14%|
|3 months (2021-07-27)||5.34%|
|6 months (2021-04-27)||-4.00%|
|1 year (2020-10-26)||117.32%|
|2 years (2019-10-25)||5.75%|
|3 years (2018-10-26)||10.8106|
|5 years (2016-10-26)||8.7817|
Valuing BGC Partners stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of BGC Partners's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
BGC Partners's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, BGC Partners shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
BGC Partners's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.22. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into BGC Partners's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$1.9 billion|
|Operating margin TTM||4.25%|
|Gross profit TTM||$1.8 billion|
|Return on assets TTM||1.64%|
|Return on equity TTM||9.92%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
There are currently 9.0 million BGC Partners shares held short by investors – that's known as BGC Partners's "short interest". This figure is 10.8% down from 10.1 million last month.
There are a few different ways that this level of interest in shorting BGC Partners shares can be evaluated.
BGC Partners's "short interest ratio" (SIR) is the quantity of BGC Partners shares currently shorted divided by the average quantity of BGC Partners shares traded daily (recently around 2.7 million). BGC Partners's SIR currently stands at 3.39. In other words for every 100,000 BGC Partners shares traded daily on the market, roughly 3390 shares are currently held short.
However BGC Partners's short interest can also be evaluated against the total number of BGC Partners shares, or, against the total number of tradable BGC Partners shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BGC Partners's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 BGC Partners shares in existence, roughly 20 shares are currently held short) or 0.0274% of the tradable shares (for every 100,000 tradable BGC Partners shares, roughly 27 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BGC Partners.
Find out more about how you can short BGC Partners stock.
Dividend payout ratio: 6.9% of net profits
Recently BGC Partners has paid out, on average, around 6.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.72% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), BGC Partners shareholders could enjoy a 0.72% return on their shares, in the form of dividend payments. In BGC Partners's case, that would currently equate to about $0.04 per share.
While BGC Partners's payout ratio might seem low, this can signify that BGC Partners is investing more in its future growth.
BGC Partners's most recent dividend payout was on 6 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 22 August 2021 (the "ex-dividend date").
BGC Partners's shares were split on a 1555:1000 basis on 2 December 2018. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1555 shares. This wouldn't directly have changed the overall worth of your BGC Partners shares – just the quantity. However, indirectly, the new 35.7% lower share price could have impacted the market appetite for BGC Partners shares which in turn could have impacted BGC Partners's share price.
Over the last 12 months, BGC Partners's shares have ranged in value from as little as $2.4189 up to $6.5025. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BGC Partners's is 2.1381. This would suggest that BGC Partners's shares are significantly more volatile than the average for this exchange and represent a higher risk.
BGC Partners, Inc. operates as a brokerage and financial technology company in the United States, Canada, Europe, the United Kingdom, Latin America, Asia, Africa, the Middle East, and internationally. It offers various brokerage products, such as fixed income, such as government bonds, corporate bonds, and other debt instruments, as well as related interest rate derivatives and credit derivatives; and fixed income, equity derivatives and cash equities, energy and commodities, shipping, insurance, and futures and options. The company also provides other services that include trade execution, brokerage, clearing, trade compression, post-trade, information, and other back office services to financial and non-financial institutions. In addition, it offers electronic brokerage, financial technology solutions, market data, post-trade services, and analytics related to financial instrument and markets under the Fenics, BGC Trader, CreditMatch, Fenics Market Data, BGC Market Data, kACE2, EMBonds, Capitalab, Swaptioniser, CBID, and Lucera brand names. Further, the company provides screen-based market solutions, which enable its clients to develop a marketplace, trade with their customers, issue debt, trade odd lots, access program trading interfaces, and access its network and intellectual property; option pricing and analysis tools; and software and technology infrastructure for the transactional and technology related elements. It primarily serves banks, broker-dealers, investment banks, trading firms, hedge funds, governments, and corporations, as well as investment firms.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.